Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on November 28th, 2023%
A developer of messenger RNA therapies for respiratory and rare diseases says it received clearance to begin a clinical trial in the U.K. for an inhaled treatment for viral lung conditions. . . . → Read More: Trial Set to Test Inhaled mRNA for Viral Infections
By Alan, on November 24th, 2023%
Researchers from university labs in the U.K. are developing models of brain cell interactions using a company’s synthetic human cells derived from stem cells. . . . → Read More: Academic, Industry Labs to Build Brain Cell Models
By Alan, on November 14th, 2023%
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria
By Alan, on October 9th, 2023%
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds
By Alan, on October 3rd, 2023%
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K. . . . → Read More: Industry-Academic Center to Boost Rare Disease Therapies
By Alan, on September 14th, 2023%
A new company spun-off from a university lab consortium is advancing gene therapies delivered through the lungs to treat rare inherited respiratory diseases. . . . → Read More: University Start-Up Developing Inhaled Gene Therapies
By Alan, on September 5th, 2023%
Results of a clinical trial show a vaccine delivered as a nasal spray protects healthy people against infection from the bacteria causing whooping cough infections. . . . → Read More: Trial Shows Nasal Vaccine Reduces Whooping Cough Bacteria
By Alan, on August 24th, 2023%
A health research foundation grant is funding development of a vaccine protecting against typhoid fever, given in a patch from from a spring-loaded device. . . . → Read More: Grant Funds Typhoid Vaccine Patch Development
By Alan, on August 11th, 2023%
Findings from two clinical trials show a digital health mobile app helps improve outcomes and manage the conditions for people with depression and asthma. . . . → Read More: Health App Shown to Improve Asthma, Depression Outcomes
By Alan, on August 2nd, 2023%
A company, spun-off from academic labs that designs and produces new chemicals with artificial intelligence and robotics, is raising $42.7 million in its first venture funding round. . . . → Read More: Digital Chemistry Start-Up Gains $43M in Early Funds
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|